Amantadine Discontinuation Strategy
Amantadine should be tapered gradually over 1-2 weeks rather than stopped abruptly to prevent withdrawal complications, particularly neuroleptic malignant syndrome-like reactions including severe hyperthermia.
Evidence for Gradual Tapering
The most compelling evidence comes from a clinical study where abrupt amantadine withdrawal in Parkinson's disease patients resulted in severe hyperthermia (39-40°C) in 2 out of 20 patients, which resolved only after reintroducing amantadine and then tapering over 15 days 1. This demonstrates that sudden discontinuation carries significant risk of serious adverse events.
Recommended Taper Schedule
For a patient on amantadine 100mg BID (200mg total daily):
Week 1:
- Reduce to 100mg once daily (50% dose reduction)
- Monitor for withdrawal symptoms including fever, rigidity, altered mental status, or autonomic instability 1
Week 2:
- Reduce to 50mg once daily (or 100mg every other day)
- Continue monitoring for withdrawal symptoms
Week 3 (if needed):
- Discontinue completely
- Observe for 3-5 days post-discontinuation for delayed withdrawal reactions 1
Critical Monitoring Parameters
Watch specifically for:
- Hyperthermia (fever >38.5°C) 1
- Worsening rigidity or motor symptoms (in Parkinson's patients)
- Altered mental status or confusion
- Autonomic instability (blood pressure changes, tachycardia)
Special Considerations by Population
Elderly Patients (≥65 years):
- These patients were likely on the maximum recommended dose of 100mg daily (not 200mg) per guidelines 2, 3, 4, 2
- If truly on 200mg daily, this exceeds guideline recommendations and increases risk of CNS side effects 2
- Taper more slowly over 3 weeks given higher baseline risk of adverse effects
Patients with Renal Impairment:
- Those with creatinine clearance <50 mL/min should have been on reduced doses already 2, 3, 4, 2
- Drug accumulation may have occurred if dosed inappropriately
- Consider slower taper (3-4 weeks) to allow adequate drug clearance
Common Pitfalls to Avoid
Never stop amantadine abruptly - The risk of neuroleptic malignant syndrome-like reactions, including potentially fatal hyperthermia, is well-documented 1. This is particularly dangerous in patients with Parkinson's disease or those on other dopaminergic medications.
Don't assume all patients tolerate the same taper speed - Women and elderly patients with smaller body size may have higher drug concentrations and require slower tapers 5.
Don't discharge patients immediately after final dose - Withdrawal symptoms can emerge 2-4 days after discontinuation 1. Ensure follow-up within one week of complete cessation.
If Withdrawal Symptoms Occur
Immediately reinitiate amantadine at the last tolerated dose 1. Once symptoms resolve (typically 3-4 days), resume tapering at a slower rate - extend the taper to 3-4 weeks total duration 1.